PUT - SPRINTER OPEN END - MODERNA | Delayed Deutsche Boerse AG 13:53:32 2024-06-18 EDT | ||
| 4.83 EUR | +11.29% |
|
| Current month | +7.69% | ||
| 1 month | -10.14% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-18 | 4.83 | +11.29% |
| 24-06-17 | 4.34 | -0.91% |
| 24-06-14 | 4.38 | +18.38% |
| 24-06-13 | 3.7 | +9.47% |
| 24-06-12 | 3.38 | -3.43% |
Delayed Quote Deutsche Boerse AG
Last update June 18, 2024 at 01:53 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
Vontobel
|
| WKN | VU2VWN |
| ISIN | DE000VU2VWN7 |
| Date issued | 2023-01-31 |
| Strike | 185.1 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.08 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.88 € |
|---|---|
| Lowest since issue | 0.47 € |
| Spread | 0.01 € |
| Spread % | 0.21% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
137.9
USD
Average target price
145.2
USD
Spread / Average Target
+5.31%
- Stock Market
- Certificates
- Certificat
